Holen Sie sich die Stockscreener-App
33.21
0.21%
0.07
Handel nachbörslich:
33.21
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Barclays PLC Raises Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by The Goldman Sachs Group to "Neutral" - MarketBeat
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings) - Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Down 5.9% in November - MarketBeat
State Street Corp Has $116.54 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
Should You Hold Apellis Pharmaceuticals (APLS)? - Insider Monkey
Old West Investment Management LLC Acquires Shares of 102,403 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 17,119 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Geographic Atrophy Market: Rapid Growth and Key Research - openPR
Apellis Pharmaceuticals Inc (APLS-Q) QuotePress Release - The Globe and Mail
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Apellis Pharmaceuticals Awards New Equity Incentives to Strengthen Executive Team - StockTitan
Cerity Partners LLC Acquires 23,749 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Fmr LLC Reduces Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report? - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
42,000 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by Erste Asset Management GmbH - MarketBeat
BNP Paribas Financial Markets Increases Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
HighVista Strategies LLC Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Bellevue Group AG Sells 425,358 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Edgestream Partners L.P. Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Braidwell LP Grows Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
APLSApellis Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionAPLS - Marketscreener.com
Zacks Research Has Bearish Estimate for APLS FY2024 Earnings - MarketBeat
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Apellis Pharmaceuticals to Present at Evercore ISI and Citi Healthcare Conferences | APLS Stock News - StockTitan
Shareholders Can't Ignore US$6.6m Of Sales By Apellis Pharmaceuticals Insiders - Simply Wall St
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Algert Global LLC - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Apellis started at equal-weight at Morgan Stanley on geographic atrophy market - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 8.8%Should You Buy? - MarketBeat
Landscape Capital Management L.L.C. Invests $776,000 in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Deep Track Capital, LP Reduces Stake in Apellis Pharmaceuticals Inc - GuruFocus.com
Deep Track Capital, LP Increases Stake in Apellis Pharmaceuticals Inc. - GuruFocus.com
Jennison Associates LLC Sells 1,770,301 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Morgan Stanley Initiates Coverage of Apellis Pharmaceuticals (APLS) with Equal-Weight Recommendation - MSN
How to Take Advantage of moves in (APLS) - Stock Traders Daily
Morgan Stanley Begins Coverage on Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts - Benzinga
Apellis Pharmaceuticals (FRA:1JK) Degree of Operating Lever - GuruFocus.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Victory Capital Management Inc. - MarketBeat
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y - MSN
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback By Investing.com - Investing.com Australia
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback - Investing.com India
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap UpTime to Buy? - MarketBeat
Apellis reiterates neutral rating, steady stock target on FDA decision - Investing.com
Apellis reiterates neutral rating, steady stock target on FDA decision By Investing.com - Investing.com UK
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):